From the Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
From the Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Am J Ophthalmol. 2024 Jul;263:126-132. doi: 10.1016/j.ajo.2024.02.001. Epub 2024 Feb 22.
Cerebral venous sinus thrombosis (CVST) is a rare but life-threatening event with significant neurologic and visual morbidity. In this study, we report on the natural history and visual outcomes of papilledema in children with CVST.
Retrospective case series.
Patients with CVST evaluated by the Department of Ophthalmology between 2000 and 2023 were included. Records were reviewed for presence and course of papilledema, treatment, and final visual outcomes following papilledema resolution.
The study included 35 patients with a mean age of 9 ± 5 years and 40% were female. The most common risk factors for CVST were infection (69%), dehydration (26%), and hypercoagulability (23%). 31 patients (89%) had papilledema. Of these patients, 9 (29%) had progression of papilledema despite treatment, 17 patients (55%) did not have progression, and 5 patients (16%) lacked follow-up records. Initial Frisén grade among all cases was 2 ± 1, and cases with progression reached a grade of 4 ± 1 between 10 and 32 days following initial identification. Most patients (97%) were treated with anticoagulation and 100% required acetazolamide and/or lumbar puncture. Among 26 patients with follow-up, papilledema resolved in 107 ± 128 days. Fifty-four percent of patients had permanent ophthalmic sequelae. An initial Frisén grade ≥3 (odds ratio 7.54, 95% confidence interval 6.53-8.70, P< .001) was significantly associated with eventual optic atrophy.
Children with CVST are at high risk for ophthalmologic sequelae. Papilledema can progress despite appropriate therapy. Our results highlight the importance of ophthalmologic follow-up during treatment course to prevent irreversible vision loss.
脑静脉窦血栓形成(CVST)是一种罕见但危及生命的疾病,可导致严重的神经和视力损伤。本研究报告了 CVST 患儿颅内压增高的自然病程和视力结果。
回顾性病例系列研究。
回顾性分析 2000 年至 2023 年间我院眼科评估的 CVST 患者。评估记录中包括颅内压增高的存在和病程、治疗以及颅内压增高缓解后的最终视力结果。
本研究共纳入 35 例 CVST 患儿,平均年龄为 9 ± 5 岁,40%为女性。CVST 的最常见危险因素包括感染(69%)、脱水(26%)和高凝状态(23%)。31 例(89%)患者存在颅内压增高。其中 9 例(29%)尽管接受了治疗,颅内压仍进展,17 例(55%)无进展,5 例(16%)缺乏随访记录。所有病例的初始 Frisén 分级为 2 ± 1,进展病例在初次发现后 10 至 32 天内达到 4 ± 1 级。大多数患者(97%)接受抗凝治疗,100%需要使用乙酰唑胺和/或腰椎穿刺。26 例有随访记录的患者中,颅内压增高缓解的中位时间为 107 ± 128 天。54%的患者存在永久性眼部后遗症。初始 Frisén 分级≥3 (优势比 7.54,95%置信区间 6.53-8.70,P<.001)与最终视神经萎缩显著相关。
CVST 患儿存在发生眼部后遗症的高风险。尽管接受了适当的治疗,颅内压仍可能进展。我们的研究结果强调了在治疗过程中进行眼科随访以预防不可逆视力丧失的重要性。